Related Experiment Video
Updated: Feb 20, 2026
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Advances in the management of HER2-positive early breast cancer
José Baselga1, Robert E Coleman2, Javier Cortés3
1Memorial Sloan Kettering Cancer Center, New York, New York, United States.
Abstract:
While trastuzumab is firmly established as the cornerstone of therapy for both early and advanced breast cancer expressing human epidermal growth factor receptor 2 (HER2), many patients either do not respond to trastuzumab treatment or progress following therapy. Improved understanding of breast cancer biology, particularly the complex signaling interactions managed by the HER family of receptors, have resulted in development of several novel HER2-directed therapies and combinations. This article will review the novel approaches to HER2 targeting that have been developed in recent years, with particular focus on results from these approaches in early breast cancer, and will discuss strategies to improve the tolerability of HER2-directed therapies, including prevention of cardiac toxicity and diarrhea.
Insights
Novel therapies targeting human epidermal growth factor receptor 2 (HER2) are emerging for breast cancer patients who do not respond to trastuzumab. This review covers new HER2-directed treatments and strategies to manage side effects like cardiac toxicity.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Trastuzumab is a standard therapy for HER2-positive breast cancer.
- A significant number of patients exhibit resistance or develop resistance to trastuzumab.
- Understanding HER2 signaling pathways is crucial for developing new treatments.
Purpose of the Study:
- To review novel HER2-directed therapies for breast cancer.
- To focus on the efficacy of these new approaches in early-stage breast cancer.
- To discuss strategies for improving treatment tolerability and managing side effects.
Main Methods:
- Review of recent clinical trials and research on novel HER2-targeted therapies.
- Analysis of treatment outcomes in early breast cancer patients.
- Examination of methods to mitigate adverse events such as cardiotoxicity and diarrhea.
Main Results:
- Several novel HER2-targeting agents and combinations have been developed.
- Emerging data show promise for these novel therapies in early breast cancer.
- Strategies for managing treatment-related toxicities are being refined.
Conclusions:
- New therapeutic strategies are expanding options for HER2-positive breast cancer.
- Addressing treatment resistance and improving tolerability are key research priorities.
- Further research is needed to optimize the use of novel HER2-directed therapies.
More Related Videos
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers